Ftse Mib
34.151,41
-0,27%
DAX
18.498,38
0,32%
S&P 500
5.187,67
0,00%
NASDAQ
16.302,76
-0,18%
Bitcoin
61.622,33
-1,14%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ OKYO Pharma Ltd (OKYO) OKYO Pharma Ltd (OKYO) Notizie

OKYO Pharma Ltd

OKYO
1,48
0,0558 (3,92%)
Dopo l'orario di negoziazione
Ultimo aggiornamento: 23:26:06
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
08/5/202413:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
08/5/202413:00GLOBEOKYO Pharma Announces Participation in May 2024 Investor..
30/4/202413:00GLOBEOKYO Pharma Announces Upcoming Presentation of OK-101 Phase..
09/4/202401:00GLOBEOKYO Pharma to Reschedule Key Opinion Leader Event in Dry..
02/4/202413:00GLOBEOKYO Pharma Announces Upcoming Presentation of OK-101 Phase..
22/3/202412:00GLOBEOKYO Pharma Announces OK-101 Successfully Achieved..
21/3/202412:00GLOBEOKYO Pharma to Host Key Opinion Leader Event to Discuss New..
20/3/202412:00GLOBEOKYO Pharma to Release New and Comprehensive Data from Phase..
09/2/202413:36IHNWOKYO Pharma Receives FDA Approval of IND for OK-101 in..
09/2/202413:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
09/2/202413:00GLOBEOKYO Pharma Receives FDA Approval of IND for OK-101 in..
31/1/202413:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
31/1/202413:00GLOBEOKYO Pharma Announces Distinguished Ophthalmologists with..
08/1/202413:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
08/1/202413:00GLOBEOKYO Pharma Announces OK-101 Successfully Achieved..
05/1/202415:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05/1/202415:30GLOBEOKYO Pharma to Present at the Biotech Showcase Conference in..
21/12/202313:35EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20/12/202323:30EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
18/12/202322:56EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
04/12/202313:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
04/12/202313:00GLOBEOKYO Pharma Announces Last Patient Enrolled in OK-101 Phase..
29/11/202313:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
01/11/202321:55EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
31/10/202321:59EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
31/10/202312:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
31/10/202312:00GLOBEOKYO Pharma Announces $5.84 Million Cash Raise and Payables..
10/10/202313:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
09/10/202317:34IHNWOKYO Pharma Announces Filing of an Investigational New Drug..
09/10/202313:00GLOBEOKYO Pharma Announces Filing of an Investigational New Drug..
05/10/202313:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05/10/202313:00GLOBEOKYO Pharma Announces Positive Safety Data Profile for the..
15/9/202322:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
15/9/202313:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
15/9/202313:00GLOBEOKYO Pharma Announces Closing of $4.0 Million Registered..
15/9/202312:05EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
14/9/202316:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
14/9/202316:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
14/9/202315:15GLOBEOKYO Pharma Announces Pricing of $4.0 Million Registered..
14/9/202314:45GLOBEOKYO Pharma Limited Announces Withdrawal of Public Offering
13/9/202322:13EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
13/9/202322:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
13/9/202322:05GLOBEOKYO Pharma Announces Public Offering of Ordinary Shares
08/9/202313:04IHNWOKYO Pharma Completes Enrollment in Phase 2 Clinical Trial..
08/9/202313:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
08/9/202313:00GLOBEOKYO Pharma Completes Enrollment in Phase 2 Clinical Trial..
30/8/202313:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
30/8/202313:00GLOBEOKYO Pharma Achieves 90% Enrollment in 240-Patient Phase 2..
29/8/202313:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
29/8/202313:00GLOBEOKYO Pharma Limited Regains Compliance with Nasdaq Listing..
Apertura: 1,45 Min: 1,4001 Max: 1,49
Chiusura: 1,4242

La tua Cronologia

NASDAQ
OKYO
OKYO Pharma
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network